Depo-Provera Brain Tumor Lawsuit

What Is This Lawsuit About?

The Depo-Provera brain tumor lawsuit is emerging litigation against Pfizer Inc. alleging that the company failed to adequately warn patients and healthcare providers about the risk of meningioma brain tumors associated with its injectable contraceptive, Depo-Provera (medroxyprogesterone acetate).

A landmark study published in the British Medical Journal (BMJ) in March 2024 found that women who used Depo-Provera for more than one year had a 5.6 times higher risk of developing meningioma compared to women who never used the drug. This finding has fueled a wave of litigation from women who were prescribed Depo-Provera without being warned about this serious risk.

Depo-Provera has been on the market since 1992 and has been used by millions of women worldwide as a long-acting contraceptive. Despite the drug containing a synthetic progestin — and despite scientific understanding that meningiomas have progesterone receptors — Pfizer's labeling did not include adequate warnings about meningioma risk. Plaintiffs allege that the manufacturer knew or should have known about this connection and failed to act.

If you or a loved one used Depo-Provera and were diagnosed with a meningioma, you may be eligible to file a claim. Learn more about related pharmaceutical lawsuits including the Ozempic stomach paralysis lawsuit and the hair relaxer cancer lawsuit.

Who Qualifies?

You may qualify for the Depo-Provera brain tumor lawsuit if you meet the following criteria. An experienced attorney can evaluate your specific case during a free consultation.

Risk Levels by Duration of Use

Research indicates that the risk of meningioma increases with the duration of Depo-Provera use. The 2024 BMJ study found the strongest association with prolonged exposure exceeding one year.

Lawsuit Timeline

The Depo-Provera brain tumor litigation is in its early stages, but is building rapidly. Here are the key milestones in this emerging mass tort:

Settlement Amounts & Projections

Because the Depo-Provera brain tumor litigation is still in its early stages, no settlements have been reached yet. However, based on comparable pharmaceutical mass tort cases, legal analysts project the following potential settlement ranges:

Settlement amounts in pharmaceutical cases are influenced by factors including severity of injury, duration of drug use, strength of medical evidence linking the drug to the condition, and the number of plaintiffs involved. For context, similar pharmaceutical product liability cases like the talcum powder lawsuit against Johnson & Johnson have resulted in multi-billion dollar settlement funds.

How to File a Claim

Filing a Depo-Provera brain tumor claim involves several steps. An experienced mass tort attorney can guide you through the process at no upfront cost.

Named Defendants

The primary defendant in Depo-Provera meningioma lawsuits is Pfizer Inc., which manufactures and markets the drug. Pfizer acquired the Depo-Provera product line through its acquisition of Pharmacia (formerly Pharmacia & Upjohn) in 2003. The original developer, Upjohn Company, brought the drug to market in 1992.

Plaintiffs allege that Pfizer (and its predecessors) knew or should have known about the link between medroxyprogesterone acetate and meningioma but failed to update the drug's labeling or provide adequate warnings to patients and prescribers.

Scientific & Medical Evidence

The connection between Depo-Provera and meningiomas is supported by growing scientific evidence:

• BMJ Study (March 2024): A large French nationwide cohort study found that prolonged use of medroxyprogesterone acetate (Depo-Provera) for more than one year was associated with a 5.6-fold increased risk of intracranial meningioma. The study analyzed data from women aged 45-74 between 2009 and 2018.
• Progesterone Receptor Biology: Meningiomas are known to express progesterone receptors in approximately 60-90% of cases. Synthetic progestins like medroxyprogesterone acetate can bind to these receptors and potentially stimulate tumor growth.
• Prior Progestin Research: Other progestin-containing medications, including cyproterone acetate (Androcur) and nomegestrol acetate, have been previously linked to meningioma risk in European studies, establishing a broader pattern of progestin-meningioma association.
• WHO/IARC Consideration: The International Agency for Research on Cancer (IARC) has classified medroxyprogesterone acetate as possibly carcinogenic to humans (Group 2B) based on available evidence.

The scientific evidence forms a key pillar of the litigation. Plaintiffs argue that this body of research should have prompted Pfizer to update its warnings long before the 2024 BMJ study brought the issue to widespread attention. Understanding the scientific basis is important — learn more about how mass tort lawsuits work and the role of scientific evidence in these cases.

What Is Depo-Provera?

Depo-Provera (depot medroxyprogesterone acetate, or DMPA) is a long-acting injectable contraceptive that has been used by millions of women since its FDA approval in 1992. Administered as an intramuscular injection once every 3 months, it works by suppressing ovulation, thinning the uterine lining, and thickening cervical mucus to prevent pregnancy.

While Depo-Provera was known to carry certain risks — including bone density loss (subject to a 2004 black box warning), weight gain, and irregular bleeding — the risk of meningioma brain tumors was not included in patient or prescriber warnings. The 2024 BMJ study findings have prompted calls for updated labeling and triggered the current wave of litigation.

Women who have been harmed by pharmaceutical products may also want to review other active lawsuits, including the hair relaxer cancer lawsuit, which also involves products disproportionately marketed to women.